Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Pharmacokinetics of dextromethorphan and metabolites in humans: influence of the CYP2D6 phenotype and quinidine inhibition.

Journal of clinical psychopharmacology - 1 Aug 1995

Schadel M, Wu D, Otton S V, Kalow W, Sellers E M

Abstract excerpt

Dextromethorphan is primarily metabolized to dextrorphan by cytochrome P450 2D6 (CYP2D6), a genetically polymorphic enzyme in humans. Dextrorphan is an active metabolite that produces phencyclidine-like behavioral effects in animals and exhibits anticonvulsant and neuroprotective properties in a variety of experimental models. In these studies, we examined the effects of CYP2D6 phenotype and quinidine inhibition...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Chromatography, High Pressure Liquid
Share to Cytochrome P-450 CYP2D6

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Cytochrome P-450 Enzyme Inhibitors

Share to Cytochrome P-450 Enzyme System

Share to Dextromethorphan

Share to Half-Life

Share to Mixed Function Oxygenases

Share to Phenotype

Source

Identifiers

PMID: 7593709
DOI: 10.1097/00004714-199508000-00005

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Pharmacokinetics of dextromethorphan and metabolites in humans: influence of the CYP2D6 phenotype and quinidine inhibition.PMID 7593709Read ↗

CYP2D6 genotype and phenotyping by determination of dextromethorphan and metabolites in serum of healthy controls and of patients under psychotropic medication.Semantic proximity Read ↗

Psychotropic effects of dextromethorphan are altered by the CYP2D6 polymorphism: a pilot study.Semantic proximity Read ↗

The consequences of 3,4-methylenedioxymethamphetamine induced CYP2D6 inhibition in humans.Semantic proximity Read ↗

Measurement of CYP2D6 and CYP3A4 activity in vivo with dextromethorphan: sources of variability and predictors of adverse effects in 419 healthy subjects.Semantic proximity Read ↗

Evaluation of cytochrome P450 2D6 phenotyping in healthy adult Western Indians.Semantic proximity Read ↗

Analysis of pharmacokinetic parameters for assessment of dextromethorphan metabolic phenotypes.Semantic proximity Read ↗

Determination of cytochrome P450 3A4/5 activity in vivo with dextromethorphan N-demethylation.Semantic proximity Read ↗

Assessment of activity levels for CYP2D6*1, CYP2D6*2, and CYP2D6*41 genes by population pharmacokinetics of dextromethorphan.Semantic proximity Read ↗

Pharmacokinetics and polymorphic oxidation of dextromethorphan in a Japanese population.Semantic proximity Read ↗

Contribution of cytochrome P-4502D6 phenotype to the neuromodulatory effects of dextromethorphan.Semantic proximity Read ↗

Polymorphism of dextromethorphan metabolism: relationships between phenotype, genotype and response to the administration of encainide in humans.Semantic proximity Read ↗

The role of CYP2D6 in primary and secondary oxidative metabolism of dextromethorphan: in vitro studies using human liver microsomes.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.